Johnson & Johnson company profile
Company profile
Johnson & Johnson has 138,200 employees and is headquartered in New Brunswick, United States.
Sales are split between the United States, which generated 57.1% of revenue, and markets outside the US, which generated 42.9%. Johnson & Johnson researches, manufactures and sells healthcare products through two segments. Innovative Medicine supplies prescription drugs for oncology, immunology and neuroscience, as well as cardiovascular and metabolic conditions, pulmonary hypertension and infectious diseases, through retailers, wholesalers, hospitals and healthcare professionals. The MedTech segment serves surgeons, physicians, nurses and eye care professionals with orthopedic, spine, cardiovascular and surgical products, including robotic systems, stapling devices and wound closure, as well as breast aesthetics and reconstruction products, contact lenses under the ACUVUE brand and intraocular lenses under the TECNIS brand.
In the fiscal year ended December 2025, revenue reached USD 94.2 billion, up 6.0% from the previous year, and net income was USD 26.8 billion. The group had 138,200 employees and is headquartered in New Brunswick, New Jersey, where it was founded in 1886.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Headquarters
- One Johnson & Johnson Plaza, 08933, New Brunswick
- Employees
- 138,200
- Chief executive
- Joaquin Duato
- Founded
- 1886
- Fiscal year
- January - December
- Listing
- JNJ · NYSE
- Currency
- USD
- ISIN
- US4781601046
- Website
- jnj.com
Johnson & Johnson and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Johnson & JohnsonJNJ | United States | $680.19B | 138,200 | 26.6% | 42.9 |
| AbbVieABBV | United States | $517.59B | 57,000 | 36.6% | 50.4 |
| Eli LillyLLY | United States | $1.28T | 50,000 | 51.3% | 46.5 |
| Merck & Co.MRK | United States | $356.13B | 73,000 | 35.2% | 144.5 |
| AmgenAMGN | United States | $250.07B | 31,500 | 34.1% | 26.8 |
| Gilead SciencesGILD | United States | $211.18B | 17,000 | 38.2% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
